Welcome to our dedicated page for Synopsys SEC filings (Ticker: SNPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synopsys, Inc. (SNPS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Synopsys common stock is registered on the Nasdaq Global Select Market, and the company regularly uses Form 8-K and other filings to report material events, financial results, and governance changes. These documents are central resources for understanding how Synopsys presents its business segments, strategic actions, and risk factors to investors.
Recent 8-K filings illustrate several themes that may be of interest to shareholders and analysts. One filing reports a restructuring plan approved by the board of directors, which is expected to affect approximately 10% of the workforce as of fiscal 2025 year-end. Synopsys states that this plan is intended to support investment in key growth opportunities and drive business efficiencies following the completion of its acquisition of Ansys, Inc., with substantial completion expected by the end of fiscal year 2027, subject to local requirements.
Other 8-Ks disclose topics such as the departure or appointment of certain officers, reaffirmation of financial targets, and the announcement of quarterly financial results. In its earnings-related filings and press releases, Synopsys reports revenue and net income on both GAAP and non-GAAP bases, provides reconciliations, and explains adjustments related to amortization of acquired intangible assets, stock-based compensation, acquisition and divestiture items, restructuring charges, and tax effects.
Filings also document regulatory and export control developments. For example, Synopsys reported receiving a letter from the U.S. Department of Commerce’s Bureau of Industry and Security rescinding previously imposed export restrictions related to China, and noted that it is working to restore access to affected products while assessing the impact of such restrictions on its business. Forward-looking statements sections in these filings outline risks and uncertainties related to macroeconomic conditions, industry trends, acquisitions, export controls, and other factors.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that highlight key items such as restructuring plans, segment disclosures, export control updates, and earnings metrics. This helps readers quickly identify the portions of Synopsys’ 8-Ks, 10-Ks, 10-Qs, and related filings that are most relevant to their analysis of SNPS.
Synopsys Inc ownership disclosure: Vanguard Capital Management reports 14,343,552 shares of Common Stock, representing 7.48% of the class as of 03/31/2026. The filing states Vanguard has sole voting power over 1,900,654 shares and sole dispositive power over 14,343,552 shares. The Schedule 13G is signed by Ashley Grim on 04/30/2026.
Synopsys, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on April 16, 2026. Stockholders approved an Amended and Restated Equity Incentive Plan that now allows non-employee directors, as well as executive officers, to receive equity awards.
They also re-elected ten directors, approved on an advisory basis the compensation of named executive officers, and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending October 31, 2026. A stockholder proposal to permit action by written consent did not receive sufficient support.
Vijayaraghavan Ravi K reported acquisition or exercise transactions in this Form 4 filing.
Synopsys Inc. director Vijayaraghavan Ravi K received an automatic stock award of 453 shares of common stock as a grant under the Amended and Restated Equity Incentive Plan. After this award, he directly holds 3,667 shares.
The shares subject to the award will vest on the date immediately preceding the first Annual Meeting following the grant date, provided he continues serving on the Board through that date.
Shimer Peter A reported acquisition or exercise transactions in this Form 4 filing.
Synopsys Inc. director Peter A. Shimer received a grant of 453 shares of common stock as an equity award. The shares were awarded at a stated price of $0.00 per share under an automatic grant from the company’s Amended and Restated Equity Incentive Plan.
These award shares will vest on the date immediately preceding the first Annual Meeting following the grant date, provided he continues Board service through that date. After this award, he directly holds a total of 1,378 shares of Synopsys common stock.
SCHWARZ JOHN reported acquisition or exercise transactions in this Form 4 filing.
Synopsys Inc. director John Schwarz received a grant of 453 shares of common stock as equity compensation. The award was granted at no cash cost per share and increased his directly held stake to 13,240 shares. According to the terms, the shares will vest on the date immediately preceding the first Annual Meeting following the grant date, as long as he continues to serve on the board until that time. The grant was made as an automatic award under Synopsys’ Amended and Restated Equity Incentive Plan.
Sargent Jeannine P reported acquisition or exercise transactions in this Form 4 filing.
SYNOPSYS INC director Jeannine P. Sargent received a stock award of 453 shares of Common Stock as board compensation. The award was granted at no cash cost on April 16, 2026 and will vest on the date immediately preceding the first Annual Meeting following the grant, if she continues serving on the board.
After this grant, she holds 2,997 shares directly. A separate line in the filing shows an additional 445 shares held indirectly by a Family Trust. The filing reflects routine equity compensation rather than an open-market stock purchase or sale.
PAINTER ROBERT G reported acquisition or exercise transactions in this Form 4 filing.
SYNOPSYS INC director Robert G. Painter received an equity award of 453 shares of Common Stock as compensation. The shares were granted at a price of $0.00 per share and are scheduled to vest on the date immediately preceding the first Annual Meeting following the grant, contingent on his continued Board service. Following this award, he directly holds 2,744 shares of Synopsys common stock.
JOHNSON MERCEDES reported acquisition or exercise transactions in this Form 4 filing.
Synopsys director Mercedes Johnson reported receiving an automatic award of 453 shares of common stock, granted at no cost under the company’s Amended and Restated Equity Incentive Plan. These shares will vest on the date immediately preceding the first Annual Meeting following the grant date, assuming continued Board service.
Johnson also reported an internal transfer of 491 previously directly held shares into the Mercedes Johnson Trust, bringing her indirectly held position through the trust to 2,390 shares. This transfer is disclosed as exempt from Section 16 under Rule 16a-13.
CHIZEN BRUCE R reported acquisition or exercise transactions in this Form 4 filing.
Synopsys Inc. director Bruce R. Chizen received an automatic equity award of 453 shares of Common Stock of Synopsys Inc. The shares were granted at a stated price of $0.0000 per share as a compensation award, not an open‑market purchase.
According to the award terms, the shares will vest on the date immediately preceding the first Annual Meeting following the grant date, provided he continues serving on the Board through that date. Following this grant, Chizen directly holds 16,162 shares of Synopsys common stock.
CHAFFIN JANICE reported acquisition or exercise transactions in this Form 4 filing.
Synopsys Inc. director Janice Chaffin received a stock award of 453 shares of common stock. The grant was made at a price of $0.00 per share as a compensation award rather than a market purchase. After this award, she directly holds 15,622 Synopsys shares.
The footnotes explain that the shares subject to this award will vest on the date immediately preceding the first Annual Meeting following the grant date, provided she continues to serve on the Board through that time. The award was granted automatically under Synopsys’ Amended and Restated Equity Incentive Plan.